Schøller J, thor Straten P, Birck A, Siim E, Dahlström K, Drzewiecki K T, Zeuthen J
Department of Tumor Cell Biology, Danish Cancer Society, Copenhagen.
Cancer Immunol Immunother. 1994 Oct;39(4):239-48. doi: 10.1007/BF01525987.
The T cell receptor (TCR) alpha beta variable (V) gene family usage of tumour-infiltrating lymphocytes (TIL) in four different primary human malignant melanomas and their corresponding metastatic lesions was characterized using a recently developed method based on the reverse-transcription-coupled polymerase chain reaction (RT-PCR). All patients were typed for HLA-A1 and -A2, either serologically or by a newly developed RT-PCR method. Two of these patients expressed HLA-A2, one the HLA-A1 haplotype and one further patient was heterozygous HLA-A1/-A2. The prognostic parameters for all four patients indicated that rapid progression of the disease was to be expected. However, only two of the patients showed rapid progression, while the remaining two patients are still alive after more than 3 years. In TIL in primary melanomas, a possible correlation was suggested between HLA-A2 and the preferential usage of the TCR V gene families V alpha 4, V alpha 5, V alpha 22 and V beta 8, whereas the V beta 3 gene family appeared to be expressed together with HLA-A1. Other highly expressed V gene families, apparently not restricted to either HLA-A1 or -A2, were V alpha 1 (expressed in three of four primary tumours) and V alpha 21 (expressed in two of four tumours). We found no evidence suggesting any correlations between the haplotypes HLA-A1 and -A2 and preferential V gene family expression in the metastatic lesions, and the only common feature was V alpha 8, which was found to be highly expressed in two out of three subcutaneous metastases. The V gene families, which were highly expressed in the primary tumour were generally not, or only very weakly, expressed in metastases and vice versa, possibly reflecting a change in the phenotype of the metastatic melanoma target cells. With regards to patient 0368, it was possible to obtain and study material from two subcutaneous metastases. The first metastasis was excised more than a year after the primary tumour, showing a completely different V region repertoire. The second metastasis was excised at surgery 2 years after primary surgery and likewise showed a dramatic shift in comparison to the first subcutaneous metastasis. Although the present study only included a small number of patients, it suggests that the estimation of V gene expression, if applied to a larger amount of patient material, might make it possible to substantiate further the suggested correlations between the T cell response against the tumour, HLA and antigen expression.(ABSTRACT TRUNCATED AT 400 WORDS)
采用一种基于逆转录偶联聚合酶链反应(RT-PCR)的最新方法,对4例不同的原发性人类恶性黑色素瘤及其相应转移病灶中肿瘤浸润淋巴细胞(TIL)的T细胞受体(TCR)αβ可变(V)基因家族使用情况进行了表征。所有患者均通过血清学或一种新开发的RT-PCR方法进行HLA-A1和-A2分型。其中2例患者表达HLA-A2,1例表达HLA-A1单倍型,另1例患者为HLA-A1/-A2杂合子。所有4例患者的预后参数表明疾病可能会快速进展。然而,只有2例患者出现了快速进展,其余2例患者在3年多后仍然存活。在原发性黑色素瘤的TIL中,提示HLA-A2与TCR V基因家族Vα4、Vα5、Vα22和Vβ8的优先使用之间可能存在关联,而Vβ3基因家族似乎与HLA-A1共同表达。其他高表达的V基因家族,显然不限于HLA-A1或-A2,有Vα1(在4例原发性肿瘤中的3例中表达)和Vα21(在4例肿瘤中的2例中表达)。我们没有发现证据表明HLA-A1和-A2单倍型与转移病灶中V基因家族的优先表达之间存在任何关联,唯一的共同特征是Vα8,在3例皮下转移灶中的2例中发现其高表达。在原发性肿瘤中高表达的V基因家族在转移灶中通常不表达或仅非常微弱地表达,反之亦然,这可能反映了转移性黑色素瘤靶细胞表型的变化。关于患者0368,有可能获得并研究来自两个皮下转移灶的材料。第一个转移灶在原发性肿瘤切除一年多后切除,显示出完全不同的V区库。第二个转移灶在原发性手术2年后手术切除,与第一个皮下转移灶相比同样显示出显著变化。尽管本研究仅纳入了少数患者,但表明如果将V基因表达评估应用于更多患者材料,可能有可能进一步证实针对肿瘤的T细胞反应、HLA和抗原表达之间所提示的关联。(摘要截短至400字)